{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:56:35Z","timestamp":1791831395906,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.eprac.2022.03.016","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:21:08Z","timestamp":1648588868000},"page":"667-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12\u2009620\u2009736 Individuals"],"prefix":"10.1016","volume":"28","author":[{"given":"Jingxuan","family":"Quek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansel Shao Pin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Meng","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Poh","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yip Han","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Jun Hao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Hui","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai En","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shadab","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Yock","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-4743","authenticated-orcid":false,"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.eprac.2022.03.016_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.016_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.22.5.341","article-title":"Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant","volume":"22","author":"Fleming","year":"1981","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.016_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.016_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.016_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.016_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.016_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.amjmed.2020.01.007","article-title":"Nonalcoholic fatty liver disease: what does the primary care physician need to know?","volume":"133","author":"Budd","year":"2020","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.016_bib8","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eprac.2022.03.016_bib9","article-title":"An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD","author":"Lim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.016_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2010.11.007","article-title":"Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?","volume":"54","author":"Targher","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.016_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.eprac.2022.03.016_bib12","doi-asserted-by":"crossref","first-page":"691696","DOI":"10.3389\/fmed.2021.691696","article-title":"Is fatty liver associated with depression? a meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease","volume":"8","author":"Xiao","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.eprac.2022.03.016_bib13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.016_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2022.03.016_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.016_bib16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9811","key":"10.1016\/j.eprac.2022.03.016_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.016_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7584","key":"10.1016\/j.eprac.2022.03.016_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","article-title":"What is heterogeneity and is it important?","volume":"334","author":"Fletcher","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2022.03.016_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11135-018-0802-x","article-title":"Fixed and random effects models: making an informed choice","volume":"53","author":"Bell","year":"2019","journal-title":"Qual Quant"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.016_bib21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.016_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn","year":"2014","journal-title":"Int J Health Policy Manag"},{"issue":"13","key":"10.1016\/j.eprac.2022.03.016_bib23","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","article-title":"Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.eprac.2022.03.016_bib24","doi-asserted-by":"crossref","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.016_bib25","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.eprac.2022.03.016_bib26","doi-asserted-by":"crossref","first-page":"693507","DOI":"10.3389\/fmed.2021.693507","article-title":"NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III","volume":"8","author":"Huang","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.016_bib27","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","article-title":"Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study","volume":"107","author":"Wang","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.03.016_bib28","doi-asserted-by":"crossref","first-page":"154779","DOI":"10.1016\/j.metabol.2021.154779","article-title":"The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis","volume":"120","author":"Liu","year":"2021","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.016_bib29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s12072-021-10252-0","article-title":"Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.016_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.03.016_bib31","article-title":"Innovative target exploration of NAFLD (ITEN) consortium. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease","author":"Moon","year":"2021","journal-title":"Gut Liver"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.016_bib32","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.016_bib33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/jcsm.12754","article-title":"Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease","volume":"12","author":"Chun","year":"2021","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.016_bib34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","article-title":"Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan","volume":"56","author":"Yoneda","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.016_bib35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/jdi.13678","article-title":"Metabolic associated fatty liver disease is a risk factor for chronic kidney disease","volume":"13","author":"Hashimoto","year":"2022","journal-title":"J\u00a0Diabetes Investig"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.016_bib36","doi-asserted-by":"crossref","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.100350","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B","volume":"3","author":"van Kleef","year":"2021","journal-title":"JHEP Rep"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.016_bib37","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.4103\/jfmpc.jfmpc_412_21","article-title":"Association of obstructive sleep apnea with nocturnal hypoxemia in metabolic-associated fatty liver disease patients: a cross-sectional analysis of record-based data","volume":"10","author":"Tomar","year":"2021","journal-title":"J\u00a0Family Med Prim Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.016_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245762","article-title":"Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study","volume":"16","author":"Niriella","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.eprac.2022.03.016_bib39","doi-asserted-by":"crossref","first-page":"154955","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu","year":"2022","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.016_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2337\/cd19-0001","article-title":"Cardiovascular outcome trials in type 2 diabetes: what do they mean for clinical practice?","volume":"37","author":"Eckel","year":"2019","journal-title":"Clin Diabetes"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.016_bib41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.016_bib42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.016_bib43","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ahj.2007.12.033","article-title":"Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial","volume":"155","author":"Zwisler","year":"2008","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.016_bib44","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2020.12.035","article-title":"Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists","volume":"74","author":"Fouad","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.016_bib45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","article-title":"The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease","volume":"75","author":"Nan","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.016_bib46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.016_bib47","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00039-2016","article-title":"A\u00a0multidisciplinary team case management approach reduces the burden of frequent asthma admissions","volume":"2","author":"Burke","year":"2016","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.016_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1378\/chest.124.1.94","article-title":"A\u00a0simple pulmonary rehabilitation program improves health outcomes and reduces hospital utilization in patients with COPD","volume":"124","author":"Hui","year":"2003","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.016_bib49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.016_bib50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review to compare FDA and EMA Guidance on drug development and endpoints in nonalcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.016_bib51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.016_bib52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","article-title":"Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22001021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22001021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:12:56Z","timestamp":1761516776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22001021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1530891X22001021"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.03.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12\u2009620\u2009736 Individuals","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}